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Abstract
Background: Anabolic resistance is the inability to increase protein synthesis in response to an increase in amino acids
following a meal. One potential mediator of anabolic resistance is endoplasmic reticulum (ER) stress. The purpose of the
present study was to test whether ER stress impairs the response to growth factors and leucine in muscle cells.
Methods: Muscle cells were incubated overnight with tunicamycin or thapsigargin to induce ER stress and the activation of
the unfolded protein response, mTORC1 activity at baseline and following insulin and amino acids, as well as amino acid
transport were determined.
Results: ER stress decreased basal phosphorylation of PKB and S6K1 in a dose-dependent manner. In spite of the decrease in
basal PKB phosphorylation, insulin (10–50 nM) could still activate both PKB and S6K1. The leucine (2.5–5 mM)-induced
phosphorylation of S6K1 on the other hand was repressed by low concentrations of both tunicamycin and thapsigargin. To
determine the mechanism underlying this anabolic resistance, several inhibitors of mTORC1 activation were measured.
Tunicamycin and thapsigargin did not change the phosphorylation or content of either AMPK or JNK, both increased TRB3
mRNA expression and thapsigargin increased REDD1 mRNA. Tunicamycin and thapsigargin both decreased the basal
phosphorylation state of PRAS40. Neither tunicamycin nor thapsigargin prevented phosphorylation of PRAS40 by insulin.
However, since PKB is not activated by amino acids, PRAS40 phosphorylation remained low following the addition of
leucine. Blocking PKB using a specific inhibitor had the same effect on both PRAS40 and leucine-induced phosphorylation of
S6K1.
Conclusion: ER stress induces anabolic resistance in muscle cells through a PKB/PRAS40-induced blockade of mTORC1.
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Introduction
Amino acids activate mTORC1 (mammalian target of rapamycin
complex 1) by promoting the exchange of GDP for GTP in the
RagA/B GTPase proteins [1,2]. When RagA/B is bound to GTP,
mTORC1 is recruited to the lysosome through its association with
the Ragulator scaffolding complex [3]. At the lysosome, mTORC1
interacts with Rheb (ras homologous enriched in brain) and is
activated [3]. The requirement of PI-3 (phosphatidyl-inositol-3)
kinase and PKB (protein kinase B/akt) for the activation of
mTORC1 by amino acids is controversial [4–7] and it has been
suggested that this process could be independent of PKB [8].
However, in some pathological states and during aging, the response
to amino acids can be altered. The inability to increase protein
synthesis in response to an increase in amino acids following a meal,
irrespective of the availability of insulin, insulin-like growth factor 1,
and growth hormone has been called anabolic resistance [9]. In
skeletal muscle, this anabolic resistance is thought to contribute to the
loss of muscle mass in aging [10]; immobilization [11]; and high-fat
feeding/obesity [12]. In spite of the fact that PKB is not necessarily
required for the amino acid-induced increase in protein synthesis and
mTORC1 activation, anabolic resistance is characterized primarily
by decreased phosphorylation of PKB.
mTORC1 is the central molecular player in anabolic resistance.
mTORC1 is composed of mTOR (a Ser/Thr protein kinase),
raptor (regulatory associated protein of mTOR) and mLST8/GbL
(G protein beta subunit-like protein) and is sensitive to the
macrolide rapamycin [13,14]. It regulates cell growth and protein
synthesis through the phosphorylation of 4EBP1 (initiation factor
4E binding protein) and S6K1 (ribosomal protein S6 kinase).
Activation of S6K1 and 4E-BP1 requires sequential phosphory-
lation events. For S6K1, phosphorylation of Ser/Thr residues in
the autoinhibitory domain, such as at Thr421 and Ser424, is
required for altering its conformation and making Thr389 and
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Thr229 available for phosphorylation, thereby fully activating
S6K1 [15]. 4E-BP1 also possesses many different phosphorylation
sites [16]. Thr37 and Thr46 phosphorylation serves as a priming
step for subsequent phosphorylation at Ser65 and Ser70 in the
carboxy-terminus that results in release from eIF4E (eukaryotic
initiation factor 4E). mTORC1 is the primary kinase for the
Thr389 site in S6K1 and the Thr37/46 sites in 4E-BP1. The other
mTOR complex, called mTORC2, is composed of mTOR, rictor
(rapamycin-insensitive companion of mTOR), mSIN1 (mamma-
lian stress-activated protein kinase-interacting protein), mLST8/
GbL and PRR5 (proline rich protein 5), and is resistant to
inhibition by rapamycin [17,18]. Activation of mTORC2 has
been shown to regulate PKB Ser473 phosphorylation [19]. PKB,
in turn, can regulate the activity of mTORC1 in three ways: 1)
PKB can directly phosphorylate mTORC1 [20]; 2) PKB can
phosphorylate and inhibit TSC2 (tuberous sclerosis complex 2) a
GTPase activating protein that targets Rheb [21]; and 3) PKB can
phosphorylate PRAS40 (prolinerich Akt substrate 40), an allosteric
inhibitor of mTORC1 [22,23]. When unphosphorylated, PRAS40
binds to raptor and prevents the association of mTORC1 with its
downstream targets. Phosphorylation of PRAS40 by PKB on
Thr246 alters its conformation such that a TOS (TOR signaling
motif) motif is unmasked. mTORC1 then phosphorylates PRAS40
on Ser183 and Ser221, resulting in dissociation of PRAS40 and
allosteric activation of mTORC1 [22].
One potential mediator of anabolic resistance is endoplasmic
reticulum (ER) stress [24–28]. Periods of high lipids, glucose
deprivation, or increased synthesis of secretory proteins lead to the
accumulation of unfolded or misfolded proteins within the ER lumen
[29]. To cope with this ER stress, cells activate the unfolded protein
response, a series of events that serve to restore ER function [30]. The
unfolded protein response has three main effectors: ATF6 (activating
transcription factor 6); IRE1a (inositol-requiring enzyme 1 alpha); and
PERK (protein kinase R-like ER protein kinase). In the basal (inactive)
state, each of these factors associates with the protein chaperone BiP/
GRP78 (binding protein/glucose regulated-protein 78), a member of
the Hsp70 (heat shock protein 70) family [31]. Upon accumulation of
unfolded/misfolded proteins, ATF6, IRE1a, and PERK are released
from BiP/GRP78 and become activated [30]. The best characterized
downstream effect of ATF6, IRE1a, and PERK release is the
induction of genes, such as XBP1 (X box binding protein 1), CHOP
(CCAAT/enhancer binding protein (C/EBP) homologous protein)
and ATF4 (activating transcription factor 4), which increase the
protein-folding capacity of the cell [30]. Concomitant with the
increase in protein folding, there is a decrease in protein synthesis that
is in part due to the phosphorylation and inhibition of eIF2a [32], and
might also be dependent on mTORC1 [28]. When the unfolded
protein response fails, the cells undergo apoptosis indicating that the
unfolded protein response is essential for normal cellular function [33].
In the present study, we sought to determine whether ER stress
could induce anabolic resistance in muscle cells. Consistent with this
hypothesis, low levels of ER stress were sufficient to prevent the
activation of mTORC1 by leucine, assessed by a decrease in S6K1
phosphorylation on Thr389, whereas at the same level of ER stress
insulin could still activate mTORC1 normally. The inability to activate
mTORC1 was not due to a lack of leucine transport, but rather to the
ER stress-induced decrease in basal PKB phosphorylation resulting in
PRAS40 hypophosphorylation and allosteric inhibition of mTORC1.
Materials and Methods
Cell cultures
C2C12 murine skeletal muscle myoblasts (ATCC, USA) were
seeded in 150 mm-diameter culture dishes and grown in Dulbeccos’s
Modified Eagle Medium (DMEM, Life technologies) supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin
(5000 U/5000 mg/ml). Cells were then plated in 6-well plates until
90% confluent. At this time, the proliferation medium was replaced
by a differentiation medium containing 2% horse serum and 1%
penicillin/streptomycin (5000 U/5000 mg/ml). After 96 h of differ-
entiation, tunicamycin (MP Biomedicals) or thapsigargin (Tocris
Bioscience) was added for 17 h in serum-free DMEM before
stimulation of the mTORC1 pathway with insulin (10–50 nM) for
15 min or with leucine (2.5–5 mM) for 30 min. Tunicamycin and
thapsigargin were used as they are well-documented chemical
inducers of ER stress by blocking N-glycosylation and calcium entry
into the ER, respectively. For PKB inhibition experiments, cells were
serum-starved for 16 h to maintain the cells in the same conditions as
those described for tunicamycin and thapsigargin experiments. PKB
inhibitor (100 nM–1 mM), also known as Akt Inhibitor XIII or Akti2
(Calbiochem), was then added 1 h before leucine (2.5–5 mM)
stimulation for 30 min. At the end of the incubation period, cells
were harvested and cell lysates were immediately frozen at 280uC
for subsequent analyses or cells were immediately used for leucine
uptake measurements. All experiments were performed at least in
duplicate.
Protein extraction, SDS/PAGE and immunoblotting
Cells were rinsed once with PBS and harvested in a lysis buffer
containing 20 mM Tris, pH 7.0, 270 mM sucrose, 5 mM EGTA,
1 mM EDTA, 1% Triton X-100, 1 mM sodium orthovanadate,
50 mM sodium b-glycerophosphate, 5 mM sodium pyrophos-
phate, 50 mM sodium fluoride, 1 mM DTT (1,4-dithiothreitol)
and a protease inhibitor cocktail containing 1 mM EDTA (Roche
Applied Science). The homogenates were then centrifuged for
10 min at 10,000 g and the supernatants were immediately stored
at 280uC. Protein concentration was determined using the DC
protein assay kit (Bio-Rad Laboratories).
Cell lysates (15 mg) were combined with Laemmli sample buffer
and separated by SDS/PAGE. After electrophoretic separation at
40 mA for 1 h, the proteins were transferred to nitrocellulose
membrane at 100 V for 1 h for western blot analysis. Membranes
were then incubated in a 5% Blotto solution. Subsequently,
membranes were incubated with the following antibodies
overnight at 4uC: eEF2; S6K1; phospho-S6K1 Thr389 and
Thr421/Ser424; phospho-PKB Ser473 and Thr308; phospho-
PRAS40 Thr246; phospho-mTOR Ser2448; phospho-PDK1
Ser241; phospho-4E-BP1 Thr37/46; phospho-GSK3 Ser9/21;
BiP; IRE1a; phospho-PERK Thr980; and phospho-eIF2a Ser51.
All antibodies were from Cell Signaling except phospho-S6K1
Thr421/Ser424 and S6K1 that were acquired from Santa Cruz
and phospho-PRAS40 acquired from Invitrogen.
Membranes were washed in TBST and incubated for 1 h at
room temperature in a secondary antibody conjugated to
horseradish peroxidase. After an additional 3 washes, chemilumi-
nescence detection was carried out using an Enhanced Chemilu-
minescent Western blotting kit (ECL Plus, GE Healthcare). The
films were then scanned on an ImageScanner using the Labscan
software and quantified with the Image Master 1D Image Analysis
Software (GE Healthcare). Equal loading was checked by probing
membranes with an anti-eEF2 as previous experiments showed
that the different treatments used in the present study did not
affect eEF2 expression.
RNA extraction and quantitative Real-Time PCR
Total RNA from the cells of one 35 mm-well (6-well plates) was
extracted with 0.5 ml TriPure reagent according to the instruc-
tions provided by the manufacturer (Roche Diagnostics). RNA was
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quantified by spectrophotometry (260 nm) and its concentration
adjusted to 1 mg/ml using RNase-free water. cDNA was prepared
by reverse transcription of 1 mg total RNA using the reverse
transcription system (Promega). SYBRHGreen (Sigma Aldrich) was
used for real-time PCR detection using an Eppendorf Light Cycler
PCR machine. Real-time PCR primers were designed (Table 1)
for mouse CHOP, ATF4, spliced (s) XBP1, unspliced (u) XBP1,
TRB3, LAT1, SNAT2, 4F2hc, ASC1, cMyc, MAD1 and
GAPDH. Specific primers were designed to recognize the spliced,
or active, form of XBP1 (XBP1s) versus the unspliced form
(XBP1u). GAPDH was used as the reference gene and the Ct for
GAPDH was unchanged by the treatments. All samples were run
in triplicate in a single 96-well reaction plate and the data were
analyzed according to the 22DDCt method. The identity and purity
of the amplified product was checked through analysis of the
melting curve carried out at the end of amplification.
Leucine uptake measurement
At the end of the 17 h incubation with tunicamycin and
thapsigargin, cells were washed with Hepes-buffered saline (HBS:
140 mM NaCl, 20 mM Hepes, 5 mM KCl, 2.5 mM MgSO4 and
1 mM CaCl2, pH 7.4), pre-warmed at 37uC. Cells were incubated
for 1 min with 0.25 mCi (or 0.5 mCi) [14C]leucine diluted in 500 ml
HBS containing 10 mM (or 1 mM) leucine. The doses of cold
leucine were chosen to be below the Km of the transporter and
about ,10 times higher (Km=,100 mM, [34,35]). Medium was
aspirated before washing cells 2 times with 0.9% (w/v) ice-cold
NaCl containing 100 mM leucine. Cells were subsequently lysed
in 50 mM NaOH, and radioactivity was quantified using a
Beckman LS 6000IC scintillation counter. Specific activity was
determined in each well by measuring radioactivity in the
incubation medium. Protein concentration in cell lysates was
determined using the DC Protein Assay (Bio-Rad). Leucine uptake
was reported to protein content and expressed as fold control. The
experiment was repeated three times and the results are presented
as the mean.
Results
ER stress is induced proportionally to tunicamycin and
thapsigargin concentrations
Increasing doses of tunicamcyin (0–5000 ng/ml, Figure 1A) and
thapsigargin (0–2000 nM, Figure 1B) increased BiP and IRE1a
protein and the phosphorylation of PERK (Thr980) and eIF2a
(Ser51) whereas the phosphorylation of PKB (Ser473) and S6K1
(Thr389) decreased. The decrease in phospho-PKB and phospho-
S6K1 correlated with the increase in BiP suggesting a common
mechanism (Pearson product moment correlation; r =20.85,
P,0.05). Tunicamycin (Figure 1C and D) and thapsigargin
(Figure 1E and F) increased CHOP, XBP1s and TRB3 mRNA
more than 30-fold. The activation of TRB3 was of particular
interest since it is known to impair PKB activation [36]. ATF4
mRNA was more than doubled by tunicamycin and thapsigargin
whereas XBP1l only increased with tunicamycin (Figure 1C–F).
ER stress decreases leucine-induced phosphorylation of
PKB and S6K1
Tunicamycin (Figure 2A) and thapsigargin (Figure 2B) not only
decreased basal phosphorylation of PKB (Ser473) and S6K1
(Thr389) but also repressed leucine-induced phosphorylation of
S6K1 (Thr389) at all concentrations from 100 ng/ml for
tunicamycin and 200 nM for thapsigargin.
ER stress decreases insulin-induced phosphorylation of
PKB and S6K1
Tunicamycin (Figure 3A) and thapsigargin (Figure 3B) also
repressed insulin-induced phosphorylation of PKB and S6K1, but
this repression was not complete. The effects of tunicamycin were
stronger than thapsigargin at all concentrations. Insulin-induced
phosphorylation of PKB was already partially repressed by 10 ng/
ml tunicamycin, considered as a low dose according to previous
reports [37], whereas 1000 nM thapsigargin, a large dose [38],
was necessary to observe a similar inhibition. Dithiothreitol (1 mM,
Figure 3A) and palmitic acid (1 mM, Figure 3B) were used as
additional controls to which tunicamcyin and thapsigargin could
be compared, as they are also known to induce ER stress. It is
important to note that the concentration of TG required to reduce
PKB/S6K1 phosphorylation following leucine stimulation was
much less than after insulin stimulation (200 nM vs. 1000 nM).
Leucine transport is not involved in the impairment of
mTORC1 activity by ER stress
We first hypothesized that the greater sensitivity of leucine
stimulation to ER stress was due to a decrease in leucine uptake.
To test this hypothesis, we analysed the expression of transporters
known to be directly or indirectly involved in leucine transport in
skeletal muscle: LAT1, SNAT2 and ASC1, as well as adaptors and
regulators of these transporters: 4F2hc, cMyc, and MAD. Tunica-
mycin and thapsigargin increased expression of 4F2hc and cMyc and
Table 1. Sequences of primers used for mRNA quantification
by real-time RT-PCR.
Forward Reverse
CHOP CCT AGC TTG GCT
GAC AGA GG
CTG CTC CTT CTC CTT
CAT GC
ATF4 GAG CTT CCT GAA
CAG CGA AGT G
TGG CCA CCT CCA GAT
AGT CAT C
XBP1s GAG TCC GCA GCA
GGT G
GTG TCA GAG TCC ATG
GGA
XBP1u AAG AAC ACG CTT
GGG AAT GG
ACT CCC CTT GGC CTC
CAC
TRB3 TGT GAG AGG ACG
AAG CTG GTG
TCG TGG AAT GGG TAT
CTG CC
LAT1 GCT GCC TGC ATC
TGT CTC TTA AC
CTG CAA TCA GCG CCA
ACA C
SNAT2 TCT TGT CCT TCA CCA
ATT TGC TC
CCC CAA TGA ACC CGA
AGA TG
4F2hc CTT TCA CAT CCC AAG
ACC TGT AAG
GAG GAA GAC AGT GCA
TGG AAG TC
ASC1 CCA CGC GCA TCC
AGG TTA
GGT GTC ATC CAG AAG
GCG AAG
cMyc CAC CAG CAG CGA
CTC TGA AGA
ATG AGC CCG ACT CCG
ACC
MAD1 CAA GCC GAC ACA
CCA CTC TGA
ACG CTG TCC ATC CGA
GTC C
GAPDH TGG AAA GCT GTG
GCG TGA T
TGC TTC ACC ACC
TTC TTG AT
CHOP, C/EBP (CCAAT/enhancer binding protein) homologous protein; ATF4,
activating transcription factor 4; XBP1s, spliced X Box binding protein 1; XBP1u,
unspliced X Box binding protein 1; TRB3, tribbles homolog 3; LAT1, L-type
amino acid transporter 1; SNAT2, sodium-coupled neutral amino acid
transporter 2; 4F2hc, 4F2 heavy chain; ASC1, sodium-independent alanine-
serine-cysteine transporter 1; MAD1, mitotic arrest-deficient 1; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0020993.t001
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decreased the expression of LAT1 and MAD1 in a dose-dependent
manner (Figure 4A–D). Since LAT1, the primary leucine transporter
in muscle, expression was decreased, leucine uptake was determined
at two different concentrations based on the transport kinetics
(Km=,100 mM, [34,35]): a non-saturating dose (10 mM, Figure 4E)
and a saturating dose (1 mM, Figure 4F). Contrary to our hypothesis,
at both concentrations, leucine uptake was slightly increased by
tunicamycin (,40%) and thapsigargin (,60%).
PRAS40 phosphorylation by PKB is required for amino
acid-induced mTORC1 activity
After determining that leucine uptake was not limiting, we next
established the point at which ER stress interrupted the activation
of mTORC1, by assessing changes in the phosphorylation of
S6K1 on Thr389. As with the Ser473 site, basal phosphorylation
of PKB at Thr308 was decreased following treatment with
tunicamycin (1000 ng/ml) and thapsigargin (1000 nM). Tunica-
Figure 1. Dose-response curves of tunicamycin and thapsigargin on ER stress markers and mTORC1 pathway. Effect of increasing
doses of tunicamycin (A) and thapsigargin (B) on BiP and IRE1a expression and PERK (Thr980), eIF2a (Ser51), PKB (Ser473) and S6K1 (Thr389)
phosphorylation after 17 h incubation. Effect of low doses of tunicamycin (C) and thapsigargin (E) and high doses of tunicamycin (D) and
thapsigargin (F) on CHOP, ATF4, XBP1s, XBP1l and TRB3 mRNA level after 17 h incubation. TN, tunicamycin; TG, thapsigargin; BiP, binding protein;
IRE1a, inositol-requiring enzyme 1 alpha; PERK, protein kinase R-like ER protein kinase; eIF2a, eukaryotic initiation factor 2 alpha; PKB, protein kinase
B; S6K1, ribosomal protein S6 kinase 1; CHOP, C/EBP (CCAAT/enhancer binding protein) homologous protein; ATF4, activating transcription factor 4;
XBP1s, spliced X Box binding protein 1; XBP1u, unspliced X Box binding protein 1; TRB3, tribbles homolog 3.
doi:10.1371/journal.pone.0020993.g001
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mycin decreased Thr308 phosphorylation in response to both low
and high levels of insulin. The inhibitory action of thapsigargin
was less potent, decreasing Thr308 phosphorylation at low but not
high levels of insulin. Even though tunicamcyin and thapsigargin
decreased PKB phosphorylation, the phosphorylation of PRAS40
on Thr246 was still enhanced by insulin, indicating that following
insulin stimulation tunicamycin and thapsigargin did not repress
mTORC1 via PRAS40. As with Thr389, the phosphorylation of
S6K1 on Thr421/Ser424 mirrored that of PKB. When PKB
phosphorylation was decreased, S6K1 phosphorylation followed
suit (Thr389; Figure 3 and Thr421/Ser424; Figure 5). Neither
PDK1, p38, ERK1/2, nor JNK phosphorylation was decreased by
either tunicamycin or thapsigargin (data not shown).
Since activation of mTORC1 by amino acids generally occurs
independent of PKB, it was not surprising that PKB phosphorylation
was not changed by the addition of leucine (Figure 5B). As described
above, tunicamycin and thapsigargin decreased basal PKB phos-
phorylation and this was also true after leucine treatment. The
phosphorylation of PRAS40 on Thr246 followed the same pattern,
completely absent in the presence of either tunicamycin or
thapsigargin. As expected, in untreated cells leucine increased the
phosphorylation of S6K1 on Thr421/Ser424 and 4EBP1 on Thr37/
46. Tunicamycin and thapsigargin completely prevented both of
these leucine-induced changes. As mentioned in the introduction,
activation of 4E-BP1 is a two-step event that first requires the
phosphorylation of Thr37/46. When 4E-BP1 is less active after
Figure 2. Effect of tunicamycin and thapsigargin on leucine-induced phosphorylation of S6K1 (Thr389). Cells were incubated for 17 h
with different doses of tunicamycin (A) or thapsigargin (B) before stimulation with 2.5 mM or 5 mM leucine for 30 min. TN, tunicamycin; TG,
thapsigargin; S6K1, ribosomal protein S6 kinase 1; Leu, leucine.
doi:10.1371/journal.pone.0020993.g002
Figure 3. Effect of tunicamycin and thapsigargin on insulin-induced phosphorylation of PKB (Ser473) and S6K1 (Thr389). Cells were
incubated for 17 h with different doses of tunicamycin (A) or thapsigargin (B) before stimulation with 10 nM or 50 nM insulin for 15 min. TN,
tunicamycin; TG, thapsigargin; PKB, protein kinase B; S6K1, ribosomal protein S6 kinase 1; Ins, insulin; DTT, dithiotreitol; PA, palmitic acid.
doi:10.1371/journal.pone.0020993.g003
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treatment with tunicamycin or thapsigargin, the phosphorylation
state of Thr37 and Thr46 remains high. Under serum-starvation
conditions, Thr37 and Thr46 phosphorylation can remain high [16].
Following a second stimulus, such as insulin, 4E-BP1 becomes
phosphorylated on Ser65 and Ser70, with a small decrease in
phosphorylation of Thr37 and Thr46 being observed [39]. Based on
the literature [39], a shift towards less fast migrating bands with
insulin can be interpreted as a higher phosphorylation state of 4E-
BP1 and a shift towards faster migrating bands with tunicamycin and
thapsigargin as a lower phosphorylation state.
We surmised that the low phosphorylation of PKB and PRAS40
resulted in the allosteric inhibition of mTORC1 in response to
leucine. To test this hypothesis, PKB activity was blocked
chemically [40] and the resulting effect on PRAS40 and leucine
Figure 4. Dose-response curves of tunicamycin and thapsigargin on amino acid transport regulation and leucine uptake. Effect of
low doses of tunicamycin (A) and thapsigargin (C) and high doses of tunicamycin (B) and thapsigargin (D) on the mRNA level of amino acid
transporters and amino acid transporters regulators after 17 h incubation. Effect of increasing doses of tunicamycin and thapsigargin on the uptake
of 10 mM (E) and 1 mM (F) leucine. TN, tunicamycin; TG, thapsigargin; LAT1, L-type amino acid transporter 1; SNAT2, sodium-coupled neutral amino
acid transporter 2; 4F2hc, 4F2 heavy chain; ASC1, sodium-independent alanine-serine-cysteine transporter 1; MAD1, mitotic arrest-deficient 1; leu,
leucine.
doi:10.1371/journal.pone.0020993.g004
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stimulation of S6K1 was determined (Figure 5C). Consistent with
our hypothesis, in the presence of the PKB inhibitor neither
PRAS40 nor S6K1 were phosphorylated, indicating that PKB is
permissive for the activation of mTORC1 by amino acids
(Figure 5B and [7]).
In summary, whereas ER stress only partially prevents insulin
stimulation of PKB and mTORC1, the lack of activation of PKB
by amino acids results in a complete block of leucine-stimulated
activation of targets downstream of mTORC1 likely through
hypophosphorylation of the mTORC1 kinase inhibitor PRAS40.
Discussion
The main finding of the present study is that ER stress induces
anabolic resistance in muscle cells through PKB/PRAS40-induced
blockade of mTORC1. Anabolic resistance is defined as the
inability to increase protein synthesis in response to an increase in
amino acids following a meal [9] or other anabolic stimuli [10,41].
The molecular mechanisms behind anabolic resistance are not
well understood although decreased expression and phosphoryla-
tion of amino acid sensing/signaling proteins, such as mTORC1
and S6K1, seem to be involved [10]. The present study has
identified the inactivation of PKB as a likely mechanism
underlying ER stress-induced anabolic resistance. High levels of
insulin, which continue to activate PKB under ER stress, albeit to
a lesser degree, can partially overcome anabolic resistance.
However, since amino acids do not normally activate PKB, the
competitive inhibitor of mTORC1, PRAS40, remains hypopho-
sphorylated and prevents the phosphorylation of mTORC1
targets such as S6K1 and 4EBP. This phenotype is replicated by
the PKB inhibitor Akti suggesting that basal PKB activity is
required for amino acid induced activation of mTORC1. We also
show that the effect of ER stress on mTORC1 is dose-dependent
since the rise in BiP expression occurred proportionally with a
decrease in PKB and S6K1 phosphorylation. This relationship
suggests that part of the ER stress response is to block PKB and
mTORC1 in an effort to decrease protein synthesis.
It should be mentioned that when cells were stimulated with
insulin, this was made in presence of basal levels of leucine
(0.8 mM) usually found in cell culture medium, whereas when cells
were stimulated with extra leucine (2.5 or 5 mM), there was no
insulin or serum. As insulin is known to play a permissive role in
the action of amino acids on the mTORC1 pathway, it is possible
that the effect of additional leucine was relatively less optimal
compared to insulin. This could have contributed to the fact that
ER stress was more potent in reducing leucine- than insulin-
induced stimulation of mTORC1.
Having previously established a negative relation between ER
stress and the mTORC1 pathway [28], the current work focussed
on determining the mechanism underlying this effect. We found
that two inhibitors of PKB/mTORC1, TRB3 [36] and REDD1
[25], were transcriptionally increased by ER stress. Even though
both of these inhibitors could be increased by ER stress, the effect
on REDD1 was minor and only seen with thapsigargin, indicating
that REDD1 was not a key player in ER stress-induced anabolic
resistance. TRB3 on the other hand was increased over 30-fold by
both ER stress agents. TRB3 directly binds to and inhibits the
kinase activity of PKB [36]. In our basal conditions, PKB activity,
as determined by phosphorylation of PRAS40 on Thr246, was
decreased consistent with the published effects of elevated TRB3.
Recently, Chen et al showed that both TN and TG could also
increase the phosphorylation of rictor at Ser1235 [42]. The
phosphorylation of rictor on this residue, like TRB3, decreases
mTORC2 activity towards PKB at Ser473, and is completely
Figure 5. Effect of tunicamycin and thapsigargin on insulin or leucine-induced phosphorylation of proteins regulating or regulated
by the mTORC1 pathway. Cells were incubated for 17 h with 1000 ng/ml tunicamycin or 1000 nM thapsigargin before stimulation with 10 nM or
50 nM insulin for 15 min (A) or with 2.5 mM or 5 mM leucine for 30 min (B). (C) Phosphorylation of S6K1 (Thr389) and PRAS40 (Thr246) after PKB
inhibition and/or leucine stimulation. Cells were serum-starved for 16 h, pre-incubated with 100 nM, 500 nM or 1 mM PKB inhibitor (Akti) for 1 h and
stimulated with 2.5 mM or 5 mM leucine in combination to Akti or not for 30 min. TN, tunicamycin; TG, thapsigargin; PKB, protein kinase B; PRAS40,
proline-rich Akt substrate 40 kDa; GSK3, glycogen synthase kinase-3; PDK1, phosphoinositide-dependent kinase 1; mTOR, mammalian target of
rapamycin; S6K1, ribosomal protein S6 kinase 1; 4E-BP1, eukaryotic initiation factor 4E-binding protein 1; eEF2, eukaryotic elongation factor 2; Ins,
insulin; Leu, leucine.
doi:10.1371/journal.pone.0020993.g005
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consistent with the decrease in PKB and mTORC1 activity we
describe here. However, insulin stimulation could partially or even
totally reverse the physiologic blockade of PKB, indicating that the
effect of TRB3 is reversible. The situation is different with leucine,
as amino acids do not activate PKB in myotubes. We speculated
that if PKB activity was decreased and PKB was permissive in
mTORC1 activation by amino acids, that leucine would be unable
to activate S6K1 and 4EBP downstream of mTORC1. Consistent
with this hypothesis, ER stress prevented S6K1 and 4EBP
phosphorylation in response to leucine. The fact that this effect
was due to inhibition of PKB was confirmed using a specific
inhibitor: Akti [40]. Both ER stress and Akti decreased PRAS40
phosphorylation as well as that of S6K1 and 4EBP. PKB
phosphorylates PRAS40 on Thr246 resulting in the unmasking
of a TOS motif that allows the phosphorylation of PRAS40 on
Ser183 and Ser221 by mTORC1 [22]. Together, these phos-
phorylation events lead to disassociation from raptor in favor of
binding to 14-3-3. The dissociation of PRAS40 allows mTORC1
to bind to its downstream targets such as S6K1 and 4EBP [22].
These data show that a permissive level of PKB activity, likely
through phosphorylation of PRAS40, is necessary for leucine to
increase the phosphorylation of S6K1 and 4EBP by mTORC1.
This is in agreement with recent data from the heart where
phosphorylation of PRAS40 is required for leucine to increase
S6K1 activity [43]. However, using a knockin mutation where
PDK1 phosphorylation of PKB is maintained but S6K activation
is prevented, they showed that the phosphorylation of PRAS40
was prevented along with leucine signaling to S6K1 [43]. These
data suggest that there may be another PRAS40 kinase responsible
for anabolic resistance in response to ER stress.
Another possible mechanism of anabolic resistance is a decrease in
amino acid transporter levels and/or amino acid uptake. Several
transporters are known to participate directly or indirectly in leucine
transport in muscle cells. The preferred transporter for leucine is the
system L-type [44] which is sodium-independent. The L-type
transporter is a heterodimeric complex made up of a light subunit,
LAT1 or LAT2, that functions as an amino acid permease and a
glycosylated heavy subunit, 4F2hc also known as CD98 [45]. Another
class of amino acid transporters that plays an indirect role in leucine
transport is the sodium-dependent system A-type, which includes
SNAT2 and ASC1. LAT1-4F2hc and SNAT2 are involved in muscle
growth and their expression has been correlated with mTORC1
activation [4,46], whereas inhibitors of SNAT2 and 4F2hc reduce
mTORC1 activity and protein synthesis [47,48]. SNAT2 and LAT1-
4F2hc work together to increase leucine uptake in a process called
tertiary active transport. Tertiary active transport uses the sodium
gradient established by the Na/K ATPase to drive sodium-dependent
uptake of glutamine through SNAT2. Once in the cell, glutamine
exchange for leucine through LAT1-4F2hc increases the influx of
leucine [49]. Consistent with the hypothesis that ER stress decreased
leucine uptake, LAT1 mRNA was decreased by thapsigargin and
tunicamycin. However, this did not lead to a decrease in leucine
uptake. The maintenance of leucine transport in the face of decreased
LAT1 mRNAmay be due to the compensatory increase in 4F2hc and
SNAT2. An increase in 4F2hc would mobilize any LAT1 protein to
the membrane and an increase in SNAT2 would provide a larger
glutamine gradient to enhance the exchange properties of any LAT1-
4F2hc transporters that were at the membrane. However, whether
prolonged ER stress would result in decreases in leucine uptake still
needs to be determined. As mTORC1 can regulate LAT1 expression
[46], a decrease in mTORC1 activity probably participated in the
decreased LAT1 mRNA expression. In summary, the anabolic
resistance following acute ER stress is not due to a decrease in amino
acid uptake as the latter tended to increase. This is consistent with in vivo
studies that have shown that anabolic resistance is not due to reduced
amino acid availability [41].
In C2C12 muscle cells, ER stress seems to impair mTORC1 rather
than vice versa [26,27]. We have previously shown that hyperactivation
of mTORC1 by insulin for 6 h or 24 h did not trigger the unfolded
protein response whereas tunicamycin activated the unfolded protein
response before S6K1 phosphorylation decreased, suggesting that in
C2C12muscle cells the induction of ER stress precedes the impairment
in mTORC1 activity [28].
The present study suggests that ER stress is a potential mediator
of the anabolic resistance observed in the muscle of aged [10],
immobilized [11], and obese [12] animals. In vitro, ER stress
completely blocks any effect of amino acids on S6K1 and 4EBP
phosphorylation, whereas the effect on insulin was less dramatic.
This is in accordance with the fact that anabolic resistance in vivo is
mainly due to decreased sensitivity to amino acids and impaired
mTORC1 signaling, rather than an impaired response to insulin
[9]. In conclusion, the present study shows that ER stress induces
anabolic resistance in muscle cells through a PKB-dependent,
PRAS40-induced, blockade of mTORC1.
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